title: Hepatitis C and didanosine: risk of lactic acidosis.
abstract: (1) In patients who are infected with both HIV and hepatitis C virus (HCV), treatment of hepatitis C slightly increases the risk of lactic acidosis associated with antiretroviral treatment, especially when the latter includes didanosine. (2) If a modification in antiretroviral treatment is needed and if treatment for hepatitis C is likely to be necessary, then it is best to avoid didanosine. However, systematic replacement of didanosine is not necessary, given the small magnitude of risk of lactic acidosis. (3) Fatigue, digestive problems, weight loss and dyspnea are signs of lactic acidosis.
mesh_terms: D000140:Acidosis, Lactic / Q000139:chemically induced*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D015897:Comorbidity; D000075202:Contraindications; D016049:Didanosine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D011994:Recombinant Proteins; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D018894:Reverse Transcriptase Inhibitors; D012254:Ribavirin; D016049:Didanosine